- Home
- KIO vs ATAI Comparison
KIO vs ATAI Comparison
Compare KIO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIO
- ATAI
- Stock Information
- Founded
- KIO 2011
- ATAI 2018
- Country
- KIO United States
- ATAI Germany
- Employees
- KIO 2400
- ATAI N/A
- Industry
- KIO Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- KIO Finance
- ATAI Health Care
- Exchange
- KIO Nasdaq
- ATAI Nasdaq
- Market Cap
- KIO 522.7M
- ATAI 444.7M
- IPO Year
- KIO N/A
- ATAI 2021
- Fundamental
- Price
- KIO $12.56
- ATAI $4.61
- Analyst Decision
- KIO
- ATAI Strong Buy
- Analyst Count
- KIO 0
- ATAI 3
- Target Price
- KIO N/A
- ATAI $13.33
- AVG Volume (30 Days)
- KIO 136.5K
- ATAI 5.2M
- Earning Date
- KIO 01-01-0001
- ATAI 08-14-2025
- Dividend Yield
- KIO 10.82%
- ATAI N/A
- EPS Growth
- KIO N/A
- ATAI N/A
- EPS
- KIO N/A
- ATAI N/A
- Revenue
- KIO N/A
- ATAI $2,309,000.00
- Revenue This Year
- KIO N/A
- ATAI $661.36
- Revenue Next Year
- KIO N/A
- ATAI N/A
- P/E Ratio
- KIO N/A
- ATAI N/A
- Revenue Growth
- KIO N/A
- ATAI 510.85
- 52 Week Low
- KIO $10.52
- ATAI $1.03
- 52 Week High
- KIO $13.59
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- KIO 50.24
- ATAI 58.43
- Support Level
- KIO $12.38
- ATAI $4.50
- Resistance Level
- KIO $12.69
- ATAI $4.99
- Average True Range (ATR)
- KIO 0.08
- ATAI 0.35
- MACD
- KIO 0.02
- ATAI -0.04
- Stochastic Oscillator
- KIO 58.06
- ATAI 34.08
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.